Masimo's (MASI) "Buy" Rating Reaffirmed at Stifel Nicolaus

Stifel Nicolaus reaffirmed their buy rating on shares of Masimo (NASDAQ:MASI - Free Report) in a research note released on Friday,Benzinga reports. Stifel Nicolaus currently has a $190.00 target price on the medical equipment provider's stock, up from their previous target price of $170.00.

MASI has been the subject of a number of other reports. Raymond James raised Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 target price for the company in a research note on Wednesday, November 6th. Needham & Company LLC restated a "hold" rating on shares of Masimo in a research report on Wednesday, November 6th. BTIG Research lifted their price objective on Masimo from $166.00 to $170.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Piper Sandler upped their target price on shares of Masimo from $165.00 to $180.00 and gave the company an "overweight" rating in a report on Wednesday, November 6th. Finally, Wells Fargo & Company upped their target price on shares of Masimo from $160.00 to $171.00 and gave the company an "overweight" rating in a report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Masimo currently has a consensus rating of "Moderate Buy" and an average target price of $167.00.

Masimo Stock Performance

Shares of MASI stock traded up $3.84 during trading hours on Friday, hitting $172.96. The stock had a trading volume of 1,036,209 shares, compared to its average volume of 648,157. The stock's 50 day moving average is $143.48 and its 200 day moving average is $128.00. The firm has a market capitalization of $9.26 billion, a PE ratio of 119.28 and a beta of 0.97. Masimo has a twelve month low of $91.60 and a twelve month high of $174.34. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. During the same period in the previous year, the business posted $0.63 earnings per share. Masimo's quarterly revenue was up 5.4% on a year-over-year basis. As a group, research analysts forecast that Masimo will post 4.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Masimo

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its position in Masimo by 41.2% during the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider's stock worth $900,860,000 after purchasing an additional 1,970,883 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Masimo by 42.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider's stock valued at $153,314,000 after acquiring an additional 360,497 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of Masimo by 107.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider's stock valued at $85,347,000 after acquiring an additional 351,523 shares in the last quarter. Bamco Inc. NY purchased a new stake in Masimo during the 1st quarter worth $50,781,000. Finally, Westfield Capital Management Co. LP increased its holdings in Masimo by 23.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider's stock valued at $185,869,000 after purchasing an additional 262,370 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.